PharmaCyte Biotech, Inc. (PMCB)
↓ Download CSV- Sector Manufacturing
- Incorporated NV
- Fiscal year ends Apr 30
In fiscal 2026, PharmaCyte Biotech, Inc. reported revenue of $0. The company ran a net loss. It held $46.75M in total assets against $11.77M in total liabilities.
Key ratios (FY2026)
-58.3%
Return on equity
| Metric (FY) | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$6.85M | -$4.38M | -$8.52M | -$6.46M | -$4.39M | -$3.62M | -$3.83M | -$4.10M | -$6.98M | -$4.44M |
| Net Income | -$19.42M | $30.66M | $333.8K | -$4.32M | -$4.24M | -$3.55M | -$3.83M | -$4.07M | -$6.83M | -$4.44M |
| EPS (Diluted) | $-2.77 | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.45 | — | — | — | — |
| Total Assets | $46.75M | $55.17M | $59.90M | $73.28M | $90.62M | $7.40M | $6.17M | $5.78M | $6.41M | $8.67M |
| Total Liabilities | $11.77M | $3.28M | $20.39M | $586.6K | $704.4K | $724.8K | $1.08M | $742.9K | $644.2K | $580.2K |
| Shareholders' Equity | $33.29M | $51.89M | $27.65M | $72.69M | $89.92M | $6.68M | $5.09M | $5.04M | $5.77M | $8.09M |
| Cash & Equivalents | $18.60M | $15.17M | $50.18M | $68.04M | $85.40M | — | — | — | — | — |
| Operating Cash Flow | -$5.15M | -$2.98M | -$2.15M | -$3.79M | -$4.12M | -$3.33M | -$2.34M | -$2.88M | -$5.08M | -$3.34M |
| Shares Outstanding | 10.74M | 6.80M | 8.04M | 16.79M | 20.72M | 1.59M | 1.09M | 1.19B | 1.01B | 905.35M |